Tags

Type your tag names separated by a space and hit enter

Cisapride inhibits meal-stimulated gastric acid secretion and post-prandial gastric acidity in subjects with gastro-oesophageal reflux disease.
Aliment Pharmacol Ther 2002; 16(10):1819-29AP

Abstract

BACKGROUND AND AIMS

KCNQ1 potassium channels in human gastric parietal cells are thought to be involved in gastric acid secretion. As cisapride can inhibit similar channels in other tissues and is an effective treatment for nocturnal heartburn, we examined the effects of cisapride on gastric and oesophageal acidity, gastric emptying and heartburn severity in subjects with gastro-oesophageal reflux disease.

METHODS

Subjects (n = 11) had suffered from heartburn four times or more per week for at least 6 months. Gastric pH and oesophageal pH were measured before, during and after a standard meal ingested over 15 min. Each subject received placebo or 10 mg cisapride orally, 30 min before the beginning of the meal. Meal-stimulated gastric acid secretion was calculated from the amount of HCl required to titrate the homogenized standard meal to pH 2 in vitro and the time required for the pH of the ingested meal to decrease to pH 2 in vivo. Heartburn severity was assessed at 15-min intervals beginning at the end of the meal. Gastric emptying of solids was measured using a [(13)C]-octanoic acid breath test.

RESULTS

Cisapride significantly decreased meal-stimulated gastric acid secretion by 20%, decreased integrated gastric and oesophageal acidity by 50-60% and transiently increased the expiration of (13)CO(2). Cisapride did not significantly alter heartburn severity.

CONCLUSIONS

The cisapride-induced decreases in meal-stimulated gastric acid secretion, gastric acidity and oesophageal acidity in subjects with gastro-oesophageal reflux disease can account for its beneficial clinical effects. These results also raise the possibility that gastric KCNQ1 potassium channels are important in meal-stimulated gastric acid secretion and possibly in the pathophysiology of gastro-oesophageal reflux disease.

Authors+Show Affiliations

Science for Organizations, Inc., Chatham, NJ 07928, USA. gardnerj@bellatlantic.netNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

12269977

Citation

Gardner, J D., et al. "Cisapride Inhibits Meal-stimulated Gastric Acid Secretion and Post-prandial Gastric Acidity in Subjects With Gastro-oesophageal Reflux Disease." Alimentary Pharmacology & Therapeutics, vol. 16, no. 10, 2002, pp. 1819-29.
Gardner JD, Rodriguez-Stanley S, Robinson M, et al. Cisapride inhibits meal-stimulated gastric acid secretion and post-prandial gastric acidity in subjects with gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2002;16(10):1819-29.
Gardner, J. D., Rodriguez-Stanley, S., Robinson, M., & Miner, P. B. (2002). Cisapride inhibits meal-stimulated gastric acid secretion and post-prandial gastric acidity in subjects with gastro-oesophageal reflux disease. Alimentary Pharmacology & Therapeutics, 16(10), pp. 1819-29.
Gardner JD, et al. Cisapride Inhibits Meal-stimulated Gastric Acid Secretion and Post-prandial Gastric Acidity in Subjects With Gastro-oesophageal Reflux Disease. Aliment Pharmacol Ther. 2002;16(10):1819-29. PubMed PMID: 12269977.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cisapride inhibits meal-stimulated gastric acid secretion and post-prandial gastric acidity in subjects with gastro-oesophageal reflux disease. AU - Gardner,J D, AU - Rodriguez-Stanley,S, AU - Robinson,M, AU - Miner,P B,Jr PY - 2002/9/25/pubmed PY - 2003/1/30/medline PY - 2002/9/25/entrez SP - 1819 EP - 29 JF - Alimentary pharmacology & therapeutics JO - Aliment. Pharmacol. Ther. VL - 16 IS - 10 N2 - BACKGROUND AND AIMS: KCNQ1 potassium channels in human gastric parietal cells are thought to be involved in gastric acid secretion. As cisapride can inhibit similar channels in other tissues and is an effective treatment for nocturnal heartburn, we examined the effects of cisapride on gastric and oesophageal acidity, gastric emptying and heartburn severity in subjects with gastro-oesophageal reflux disease. METHODS: Subjects (n = 11) had suffered from heartburn four times or more per week for at least 6 months. Gastric pH and oesophageal pH were measured before, during and after a standard meal ingested over 15 min. Each subject received placebo or 10 mg cisapride orally, 30 min before the beginning of the meal. Meal-stimulated gastric acid secretion was calculated from the amount of HCl required to titrate the homogenized standard meal to pH 2 in vitro and the time required for the pH of the ingested meal to decrease to pH 2 in vivo. Heartburn severity was assessed at 15-min intervals beginning at the end of the meal. Gastric emptying of solids was measured using a [(13)C]-octanoic acid breath test. RESULTS: Cisapride significantly decreased meal-stimulated gastric acid secretion by 20%, decreased integrated gastric and oesophageal acidity by 50-60% and transiently increased the expiration of (13)CO(2). Cisapride did not significantly alter heartburn severity. CONCLUSIONS: The cisapride-induced decreases in meal-stimulated gastric acid secretion, gastric acidity and oesophageal acidity in subjects with gastro-oesophageal reflux disease can account for its beneficial clinical effects. These results also raise the possibility that gastric KCNQ1 potassium channels are important in meal-stimulated gastric acid secretion and possibly in the pathophysiology of gastro-oesophageal reflux disease. SN - 0269-2813 UR - https://www.unboundmedicine.com/medline/citation/12269977/Cisapride_inhibits_meal_stimulated_gastric_acid_secretion_and_post_prandial_gastric_acidity_in_subjects_with_gastro_oesophageal_reflux_disease_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0269-2813&date=2002&volume=16&issue=10&spage=1819 DB - PRIME DP - Unbound Medicine ER -